Side Effect Correlation News Today

Experts provide practical guidelines and key takeaways for health care professionals and policymakers on the implementation of bispecific antibodies in DLBCL (diffuse large B cell lymphoma), emphasizing safety, efficacy, and operational strategies.

A panel of experts examines unmet needs in the adoption of bispecific antibody therapy, emphasizing the importance of access and education for diverse stakeholders in oncology care to improve patient outcomes.

Robert Mancini, PharmD, reviews pharmacists’ pivotal role in operationalizing use of bispecifics in diffuse large B-cell lymphoma (DLBCL), overcoming challenges, and supporting direct patient care teams.

Experts discuss strategies to reduce treatment-related toxicities in bispecific antibody treatments, emphasizing clarity on dosing, hydration, and safety concerns.

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, and Amir Ali, PharmD, BCOP, FHOPA, delve into bispecific antibody treatments, focusing on strategies for patient safety and optimizing care in the management of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome.

Robert Mancini, PharmD, discusses bispecific therapy advancements and strategies to manage adverse effects in diffuse large B-cell lymphoma (DLBCL) care, offering insights on toxicity phases, monitoring, and patient care.

Health care experts provide insights into patient education, shared decision-making, and treatment monitoring in DLBCL (diffuse large B cell lymphoma) therapies, reviewing education strategies and response monitoring.